Completed PHASE2 INTERVENTIONAL 4-arm NCT00097773

Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis (EPIC)

Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients With Cystic Fibrosis

Sponsor: CF Therapeutics Development Network Coordinating Center

Conditions Cystic Fibrosis Pulmonary Disease, Chronic Obstructive

Interventions Oral ciprofloxacin Oral placebo Tobramycin solution for inhalation (TOBI)

Updated 8 times since 2017 Last updated: Jan 28, 2014 Started: Sep 30, 2004 Primary completion: Jun 30, 2009 Completion: Aug 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cystic Fibrosis and Pulmonary Disease, Chronic Obstructive and is currently completed. CF Therapeutics Development Network Coordinating Center leads this study, which shows 8 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2019 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2019 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CF Therapeutics Development Network Coordinating Center
Cystic Fibrosis Foundation
National Heart, Lung, and Blood Institute (NHLBI)
Seattle Children's Hospital

Data source: Seattle Children's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Albany, United States , Ann Arbor, United States , Atlanta, United States , Augusta, United States , Aurora, United States , Baltimore, United States , Birmingham, United States , Boston, United States , Burlington, United States and 41 more locations